Under the brand name Victoza, liraglutide is FDA approved for blood sugar control in adults with Type 2 diabetes, along with diet and exercise, and to reduce the risk of MACE in adults with both Type 2 diabetes and cardiovascular disease
Final maintenance dose : 2.4 mg weekly
The FDA declared the semaglutide shortage resolved in February 2025, with 503A compounding winding down around April 22, 2025 and 503B around May 22, 2025
Ship A Passion for Patient-Centered Care Sandra Jordan, MSN, APRN, FNP-C, is a board-certified nurse practitioner providing personalized evidence-based medical weight loss care
Individuals with higher starting body weight may experience larger reductions over time as the medication begins to regulate appetite and metabolism
What are the primary benefits of semaglutide